Neurocrine Biosciences (NBIX) FCF Margin (QoQ) (2010 - 2026)
Neurocrine Biosciences (NBIX) FCF Margin (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - |
| 10 | Alkermes | 8.20 Bn | 7.54 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -337.00 |
| Mar 31, 2026 | -3,079.00 |
| Dec 31, 2025 | 2,424.00 |
| Sep 30, 2025 | 816.00 |
| Jun 30, 2025 | 667.00 |
| Mar 31, 2025 | -2,323.00 |
| Dec 31, 2024 | 688.00 |
| Sep 30, 2024 | 1,352.00 |
| Jun 30, 2024 | -1,083.00 |
| Mar 31, 2024 | -55.00 |
| Dec 31, 2023 | -1,882.00 |
| Sep 30, 2023 | 285.00 |
| Jun 30, 2023 | 6,955.00 |
| Mar 31, 2023 | -6,803.00 |
| Dec 31, 2022 | 1,619.00 |
| Sep 30, 2022 | -67,809.00 |
| Jun 30, 2022 | 71,394.00 |
| Mar 31, 2022 | -1,243.00 |
| Dec 31, 2021 | -1,823.00 |
| Sep 30, 2021 | -1,827.00 |